We are live on ! Find out more
NVS icon

Novartis

1,561 hedge funds and large institutions have $19.1B invested in Novartis in 2026 Q3 according to their latest regulatory filings, with 105 funds opening new positions, 468 increasing their positions, 635 reducing their positions, and 141 closing their positions.

New
Increased
Maintained
Reduced
Closed

2% more capital inflows, than outflows

Capital inflows: $1.99B | Capital outflows: $1.95B

0.12% less ownership

Funds ownership: 7.15% → 7.03% (-0.12%)

5% less funds holding

Funds holding: 1,635 → 1,561 (-74)

10% less funds holding in top 10

Funds holding in top 10: 10 → 9 (-1)

26% less first-time investments, than exits

New positions opened: 105 | Existing positions closed: 141

26% less repeat investments, than reductions

Existing positions increased: 468 | Existing positions reduced: 635

50% less call options, than puts

Call options by funds: $571M | Put options by funds: $1.15B

Holders
1,561
Holders Change
-74
Holders Change %
-4.53%
% of All Funds
18.98%
Holding in Top 10
9
Holding in Top 10 Change
-1
Holding in Top 10 Change %
-10%
% of All Funds
0.11%
New
105
Increased
468
Reduced
635
Closed
141
Calls
$571​M
Puts
$1.15​B
Net Calls
-⁠$574​M
Net Calls Change
-⁠$135​M

NVS Hedge Fund Activity: Q3 2026 in Review

1,561 of the 8,226 institutional investors tracked by Wall St. Rank reported a position in Novartis (NVS) for Q3 2026, worth a combined $19.1B — down 11% from $21.4B a quarter earlier.

Sellers outnumbered buyers: 141 funds closed out of NVS and 105 opened new positions — a net loss of 36 holders — while 635 trimmed existing stakes and 468 added.

The largest buyer was Citadel Advisors, adding an estimated $196M. The largest seller was GQG Partners, cutting an estimated $319M.

  • 1,561 institutional investors held Novartis (NVS) as of Q3 2026, down from 1,635 in Q2 2026.
  • Funds reported $19.1B of Novartis stock for Q3 2026, down 11% quarter-over-quarter.
  • 105 funds opened new Novartis positions in Q3 2026 and 141 closed out, a net change of -36 holders.
  • The largest Novartis buyer in Q3 2026 was Citadel Advisors, an estimated $196M added.
  • The largest Novartis seller in Q3 2026 was GQG Partners, an estimated $319M sold.

Based on aggregated 13F filings for Q3 2026.